This report provides a summary of the current and future state of the psychedelic therapeutic sector, offering a high-level analysis of key trends and developments within the industry, including regulatory, clinical, and market dynamics. The report identifies the broader changes within the evolving psychedelic industry, facilitating informed decision-making for relevant sectors.
Scope
This 36-page report gives important, expert insight you won’t find in any other source. 12 figures throughout the report illustrate major points and trends in future pharmaceutical sales forecasts and company pipelines. This report is required reading for :
- Investors that want to understand future trends impacting the psychedelic drug industry as well as identifying companies to invest in
- Companies that are interested in entering the psychedelic drug industry and where best to focus on
- Large pharma companies with investment groups or BD teams looking to see which companies are predicted to lead the industry in the near and far future
- Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
- Insights on psychedelic drugs by development stage
- Insights on dealmaking trends
- Insights on psychedelic drugs clinical trial trends
- Insights on psychedelic drugs review designations awarded over time
- Insights on leading psychedelic companies and sponsors
- Therapeutic and Indication insights into the psychedelic drug market
Table of Contents
Executive Summary1. Psychedelic Therapeutics
- 1..1 Psychedelics Can Revolutionize Mental Health Treatments
- 1..2 Timeline of Key Events
- 2..1 Top Therapy Areas
- 2..2 Top Drug Indications
- 2..3 Top Companies
- 2..4 Drugs by Development Stage
- 2..5 Clinical Trials by Sponsor Type
- 2..6 Types of Review Designations Awarded over 10 years
- 2..7 Review Designations Awarded by Country over 10 years
- 2..8 Top Five Drugs by Likelihood of Approval (LoA)
- 3..1 Top Countries by Deal Numbers
- 3..2 Pharmaceutical Sales Forecast by Company
- 4..1 Top Psychedelic Drugs in Development
6. Appendix
- 6..1 Abbreviations
- 6..2 Related Reports
- 6..3 Methodology
- 6..4 About the Authors
- 6..5 About the Publisher
- 6..6 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Johnson & Johnson
- Otsuka Holdings Co Ltd
- Avanir Pharmaceuticals Inc
- Seelos Therapeutics Inc.
- NLS Pharmaceutics AG
- HMNC Holding GmbH
- Cingulate Inc
- Lykos Therapeutics
- Compass Pathways Plc
- Shenox Pharmaceuticals LLC
- Atai Life Sciences NV
- Mind Medicine MindMed Inc
- PharmaTher Holdings Ltd
- Cybin Inc
- Delix Therapeutics Inc
- GH Research PLC
- Filament Health Corp
- PSYLO Pty Ltd
- PharmAla Biotech Inc
